News ReleaseView printer-friendly version << Back
New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty
“The results of this analysis are encouraging because they suggest that the use of EXPAREL not only allows us to get our patients up and out of the hospital sooner, but also increases the likelihood we can send them directly home,” said
In this retrospective analysis, which was supported by Pacira, researchers reviewed data from the Premier hospital discharge database in order to identify patients ages 18 and older who underwent an inpatient TKA procedure between
Key findings for patients receiving EXPAREL compared to the standard analgesic modalities included:
- Nearly a half-day reduction in length of hospital stay (2.58 vs 2.98 days, respectively; p<0.001)
- More patients discharged directly to home rather than an interim care facility (73.2% vs 66.6%, respectively)
- A higher likelihood of being discharged home, according to a logistic regression analysis (OR=1.49 for patients in the EXPAREL group; p<0.001)
“Today’s dynamic healthcare environment of accountable care, bundled payments and patient satisfaction-driven reimbursement are evidence of the critical role of non-opioid options such as EXPAREL for postsurgical pain management,” said
EXPAREL is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with a decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at: http://www.exparel.com/hcp/pdf/EXPAREL_Prescribing_Information.pdf
Forward Looking Statements
Any statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of
Pacira Pharmaceuticals, Inc. Jessica Cho, 973-254-3574 Jessica.email@example.com Media Contact: Coyne Public Relations Alyssa Schneider, 973-588-2270 firstname.lastname@example.org